Skip to main content
Premium Trial:

Request an Annual Quote

EGeen, Prediction Sciences In Second Pharmacogenetics Collaboration

NEW YORK, Jan. 13-EGeen International and Prediction Sciences will collaborate to study the pharmacogenetics of Paxil, the two companies said today.

 

EGeen will provide the clinical data and Prediction Sciences will supply bioinformatics expertise to determine the genetic basis of patient response to this commonly prescribed anti-depressant.

 

EGeen, based in Redwood City, Calif., has exclusive commercial rights to data from the Estonian Gene Bank, a national database collecting genetic and clinical information from patients throughout Estonia. The company uses this database for drug and diagnostic discovery and for pharmacogenomic studies.

 

Prediction Sciences is a San Diego, Calif.-based private company developing bioinformatics for pharmacogenetic applications.

 

Earlier this year, the two companies struck a similar partnershipto study the pharmacogenetics of Celexa, another treatment for depression. Prediction Sciences hopes to create a comprehensive pharmacogenetic diagnostic panel to guide in the prescription of anti-depressants.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.